Sfoglia per AUTORE
KUDO M
Collezione AO Ordine Mauriziano

  

Items : 1

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial. in JAMA oncology / JAMA Oncol. 2023 Dec 1;9(12):1651-1659. doi: 10.1001/jamaoncol.2023.4003.

2023
AO Ordine Mauriziano

Zhu AX; Vogel A; Abdrashitov R; Finn RS; Boisserie F; Li S; Chen Y; Assenat E; Satoh T; Marino D; Meng Z; Bai Y; Guo Y; Meyer T; Kudo M; Qin S;